Dehydroevodiamine (Standard)

Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes[1]. Dehydroevodiamine inhibits LPS-induced iNOS, COX-2, prostaglandin E2 (PGE2) and nuclear factor-kappa B (NF-κB) expression in murine macrophage cells[2].

Product Specifications

CAS Number

[67909-49-3]

UNSPSC

12352005

Target

COX; NF-κB; NO Synthase; PGE synthase

Related Pathways

Immunology/Inflammation; NF-κB

Field of Research

Inflammation/Immunology

Smiles

O=C1N2C(C([N-]C3=C4C=CC=C3)=C4CC2)=[N+](C)C5=C1C=CC=C5

Molecular Formula

C19H15N3O

Molecular Weight

301.34

References & Citations

[1]Loh SH, et al. Antiarrhythmic effects of dehydroevodiamine in isolated human myocardium and cardiomyocytes. J Ethnopharmacol. 2014 May 14;153 (3) :753-62.|[2]Noh EJ, et al. Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages. Life Sci. 2006 Jul 10;79 (7) :695-701. Epub 2006 Mar 6.